# Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection

> **NCT05620017** · PHASE1 · RECRUITING · sponsor: **Bio-Thera Solutions** · enrollment: 182 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** BAT8008 for Injection

## Key facts

- **NCT ID:** NCT05620017
- **Lead sponsor:** Bio-Thera Solutions
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-11-30
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2026-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05620017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05620017, "Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8008 for Injection". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05620017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*